Psoriatic ArthritisPERISNCT06764693
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
An observational study of Psoriatic Arthritis, run by AbbVie at 132 sites in 15 countries.
Trial summary
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Psoriatic Arthritis
- How many people
- 1,200 participants
- Where
- 132 sitesin 15 countries
- Study dates
- 31 Jan 2025to Feb 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants that currently are treated with Risankizumab or other advanced treatment options for the management of active psoriatic arthritis in clinical practice.
Who may be able to join
- Participant with a clinical diagnosis of psoriatic arthritis (PsA) with symptom onset at least 6 months prior to the Screening visit and fulfillment of ClASsification for Psoriatic ARthritis (CASPAR) at Baseline visit to confirm that the participant has active disease.
- Participant must have demonstrated an inadequate response to at least 1 Disease-modifying antirheumatic drug (DMARD) (with max 50% Biologic DMARD-Inadequate Response); alternatively, participant must have demonstrated an intolerance to or contraindication for csDMARDs as determined by the investigator.
Who cannot join
- Participants demonstrated an inadequate response to three or more bDMARDs/targeted synthetic DMARDs (tsDMARDs).
Trial locations and contacts
132 sites in 15 countries. Contact the study team or a site near you to ask about taking part.
132 sites in 15 countries
France27 sites, 27 recruiting
- Recruiting
Hôpital Privé De Provence /ID# 275797
Aix-en-Provence, Provence-Alpes-Côte d'Azur Region, 13080
- Recruiting
Centre Hospitalier D'Arras /ID# 275192
Arras, Hauts-de-France, 62022
- Recruiting
Centre Hospitalier Regional Universitaire de Besancon - Hopital Jean Minjoz /ID# 277881
Besançon, Doubs, 25000
- Recruiting
Centre Hospitalier Boulogne-Sur-Mer /ID# 277269
Boulogne-sur-Mer, Pas-de-Calais, 62321
- Recruiting
CH de Cahors /ID# 275092
Cahors, 46005
- Recruiting
Infirmerie Protestante De Lyon /ID# 274922
Caluire-et-Cuire, Auvergne-Rhône-Alpes, 69300
- Recruiting
Centre Hospitalier De Cannes - Hôpital De Cannes /ID# 275193
Cannes, Provence-Alpes-Côte d'Azur Region, 06414
- Recruiting
Centre Hospitalier Régional Universitaire De Tours - Hôpital Trousseau /ID# 275397
Chambray-lès-Tours, Indre-et-Loire, 37170
- Recruiting
Centre Hospitalier Universitaire Gabriel-Montpied /ID# 275399
Clermont-Ferrand, Auvergne-Rhône-Alpes, 63000
- Recruiting
Centre Hospitalier Sud Francilien /ID# 275038
Corbeil-Essonnes, Île-de-France Region, 91106
- Recruiting
Henri Mondor Hospital /ID# 275360
Créteil, Val-de-Marne, 94000
- Recruiting
Chu Grenoble - Hôpital Sud /ID# 275200
Échirolles, Auvergne-Rhône-Alpes, 38130
- Recruiting
CHU de Lille - Hôpital Salengro /ID# 274980
Lille, Hauts-de-France, 59037
- Recruiting
Clinique François Chénieux /ID# 276516
Limoges, Limousin, 87039
- Recruiting
CHU Limoges - Dupuytren 2 /ID# 274918
Limoges, New Aquitaine, 87000
- Recruiting
Pôle Santé du Pont de Chaume /ID# 275608
Montauban, Occitanie, 82000
- Recruiting
Chu Montpellier /ID# 274925
Montpellier, Herault, 34295
- Recruiting
Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 275396
Nantes, Pays de la Loire Region, 44000
- Recruiting
Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 274923
Nice, Alpes-Maritimes, 06001
- Recruiting
Centre Hospitalier Régional d'Orléans - Hôpital de la Source /ID# 275377
Orléans, 45067
- Recruiting
AP-HP - Groupe Hospitalier 10e - Hopital Lariboisiere /ID# 275182
Paris, 75010
- Recruiting
Groupe Hospitalier Paris Saint-Joseph /ID# 274981
Paris, 75014
- Recruiting
Hopital Pitie Salpetriere /ID# 275368
Paris, Île-de-France Region, 75013
- Recruiting
Cabinet libéral du Dr PAUPIERE /ID# 275401
Péronne, Somme, 80200
- Recruiting
Chru De Rennes - Hôpital Sud /ID# 277115
Rennes, Ille-et-Vilaine, 35203
- Recruiting
Centre Hospitalier Universitaire de Rouen (CHU)- Hopital Charles Nicolle /ID# 275366
Rouen, Seine-Maritime, 76031
- Recruiting
Centre Hospitalier de Valenciennes /ID# 276354
Valenciennes, 59300
Germany23 sites, 22 recruiting
- Completed
Private Practice - Dr. Thomas Kupka /ID# 276236
Altenburg, Thuringia, 04600
- Recruiting
Dr. Med. Thomas Marycz /ID# 280489
Amberg, Bavaria, 92224
- Recruiting
Rheumapraxis Steglitz /ID# 279413
Berlin, 12161
- Recruiting
Private Practice - Dr. Silke Zinke /ID# 279350
Berlin, 13055
- Recruiting
MVZ Herzogin Elisabeth Hospital /ID# 275583
Braunschweig, 38114
- Recruiting
Deutsches Endokrinologisches Versorgungszentrum DEVZ - MVZ GdR /ID# 276484
Frankfurt am Main, Hesse, 60329
- Recruiting
Praxis Fiene /ID# 279363
Greifswald, 17493
- Recruiting
Rheumapraxis Dr. Liebhaber /ID# 276235
Halle, Saxony-Anhalt, 06128
- Recruiting
Praxis. F. Bigdeli-Wilshusen /ID# 275522
Hanover, Lower Saxony, 30173
- Recruiting
Private Practice - Dr. Dirk Wernicke /ID# 279748
Hohen Neuendorf, Brandenburg, 16540
- Recruiting
Praxis Dr. med. Florian Beyer /ID# 276233
Kaiserslautern, Rhineland-Palatinate, 67657
- Recruiting
Rheumatologie Kassel /ID# 276311
Kassel, Lower Saxony, 34125
- Recruiting
Universitaetsklinikum Schleswig-Holstein Campus Luebeck /ID# 275711
Lübeck, Schleswig-Holstein, 23538
- Recruiting
Rheumatologische Facharztpraxis /ID# 276359
Magdeburg, Saxony-Anhalt, 39104
- Recruiting
Klinische Forschung Im Medizinischen Versorgungalltag Gbr /ID# 276208
Planegg, Bavaria, 82152
- Recruiting
Knappschaftsklinikum Saar /ID# 279850
Püttlingen, Saarland, 66346
- Recruiting
Rheumapraxis Dr. Prothmann /ID# 275712
Püttlingen, Saarland, 66346
- Recruiting
Rheumazentrum Ratingen /ID# 278190
Ratingen, North Rhine-Westphalia, 40882
- Recruiting
Private Practice - Dr. Jochen Walter /ID# 280067
Rendsburg, Schleswig-Holstein, 24768
- Recruiting
Rheumatologisch Immunologisch /ID# 275832
Templin, Brandenburg, 17268
- Recruiting
Krankenhaus der Barmherzigen Brüder Trier /ID# 278759
Trier, Rhineland-Palatinate, 54292
- Recruiting
Rheumateam Lahn-Dill-Siegerland /ID# 276019
Wetzlar, Hesse, 35578
- Recruiting
Cellitinnen-Krankenhaus St. Josef /ID# 275710
Wuppertal, 42105
Greece16 sites, 16 recruiting
- Recruiting
University General Hospital of Alexandroupolis /ID# 272411
Alexandroupoli, Evros, 68100
- Recruiting
Athens Naval Hospital /ID# 272313
Athens, Attica, 11521
- Recruiting
General Hospital of Athens Ippokratio /ID# 262528
Athens, Attica, 11527
- Recruiting
General Hospital of Athens Laiko /ID# 272325
Athens, Attica, 11527
- Recruiting
General Hospital of Athens Laiko /ID# 272410
Athens, Attica, 11527
- Recruiting
University General Hospital Attikon /ID# 272358
Athens, Attica, 12462
- Recruiting
KAT Atttica General Hospital /ID# 271741
Athens, 14561
- Recruiting
University General Hospital of Heraklion /ID# 271743
Heraklion, Crete, 71500
- Recruiting
General Hospital of Ioannina G. Hatzikosta /ID# 272327
Ioannina, 45445
- Recruiting
The University Hospital of Larissa /ID# 272315
Larissa, Larisa, 41110
- Recruiting
Olympion General Clinic /ID# 271685
Pátrai, Achaia, 25443
- Recruiting
Bioclinic Thessaloniki /ID# 272316
Thessaloniki, 54622
- Recruiting
General Hospital of Thessaloniki Hippokrateio /ID# 272314
Thessaloniki, 54642
- Recruiting
Euromedica General Clinic of Thessaloniki /ID# 272412
Thessaloniki, 54645
- Recruiting
Euromedica General Clinic of Thessaloniki /ID# 275805
Thessaloniki, 54645
- Recruiting
Asklipieio General Hospital of Voula /ID# 272326
Voula, Attica, 16673
Italy13 sites, 13 recruiting
- Recruiting
Azienda Ospedaliero Universitaria delle Marche /ID# 264636
Ancona, 60020
- Recruiting
ASST degli Spedali Civili di Brescia /ID# 264699
Brescia, 25123
- Recruiting
Universita degli Studi del Molise /ID# 265162
Campobasso, 86100
- Recruiting
AOU Policlinico G. Rodolico - San Marco /ID# 264459
Catania, 95123
Site Coordinator, +39-957-435-045
- Recruiting
ASL 2 Abruzzo Lanciano-Vasto-Chieti /ID# 265640
Chieti, 67100
- Recruiting
ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO /ID# 265161
Milan, Milano, 20122
- Recruiting
IRCCS Ospedale San Raffaele /ID# 266212
Milan, Milano, 20132
- Recruiting
Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 266888
Naples, Napoli, 80138
- Recruiting
Azienda Ospedaliero Universitaria Pisana /ID# 264938
Pisa, 56126
- Recruiting
Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 265145
Rome, Roma, 00161
- Recruiting
IRCCS Istituto Clinico Humanitas /ID# 264463
Rozzano, Lombardy, 20089
- Recruiting
Azienda Ospedaliera Universitaria Senese /ID# 265207
Siena, 53100
- Recruiting
ASU FC - P.O. Universitario Santa Maria della Misericordia /ID# 264698
Udine, 33100
Spain11 sites, 11 recruiting
- Recruiting
Hospital Universitario Virgen de las Nieves /ID# 275741
Granada, 18014
- Recruiting
Hospital Universitario Clinico San Cecilio /ID# 272665
Granada, 18016
- Recruiting
Hospital Juan Ramón Jiménez /ID# 272667
Huelva, 21005
- Recruiting
Hospital Rafael Mendez /ID# 272663
Lorca, Murcia, 30817
- Recruiting
Hospital Universitario de La Princesa /ID# 264073
Madrid, 28006
- Recruiting
Hospital Universitario 12 de Octubre /ID# 272660
Madrid, 28041
- Recruiting
Hospital Universitario La Paz /ID# 264316
Madrid, 28046
- Recruiting
Hospital Universitario Virgen de la Victoria /ID# 264317
Málaga, Malaga, 29010
- Recruiting
Hospital General Universitario Reina Sofía /ID# 272664
Murcia, 30003
- Recruiting
Hospital Universitario de Valme /ID# 264314
Seville, Sevilla, 41014
- Recruiting
Hospital Xeral Cies (CHUVI) /ID# 272659
Vigo, Pontevedra, 36204
Belgium7 sites, 7 recruiting
- Recruiting
OLV Ziekenhuis Aalst /ID# 274456
Aalst, Oost-Vlaanderen, 9300
- Recruiting
Universite Libre de Bruxelles - Hopital Erasme /ID# 272763
Anderlecht, Brussels Capital, 1070
- Recruiting
Rhumaconsult Sprl /ID# 272797
Charleroi, Hainaut, 6000
- Recruiting
Reumacentrum Genk - Medisch Centrum Genk /ID# 272796
Genk, Limburg, 3600
- Recruiting
ReumaClinic /ID# 272782
Genk, Limburg, 3600
- Recruiting
UZ Leuven /ID# 272781
Leuven, Vlaams-Brabant, 3000
- Recruiting
CHU de Liege /ID# 272784
Liège, 4000
Bulgaria7 sites, 7 recruiting
- Recruiting
Military Hospital - Pleven /ID# 276054
Pleven, 5803
- Recruiting
Medical Center Epiona /ID# 276037
Plovdiv, 4001
- Recruiting
University Multiprofile Hospital For Active Treatment Pulmed /ID# 276157
Plovdiv, 4002
- Recruiting
Dr. Tsvetanka Petranova ELIMED - 2 /ID# 276158
Sofia, 1408
- Recruiting
Medical Center Academy /ID# 276041
Sofia, 1612
- Recruiting
Diagnostic Consultative Centre (Dcc) - Foкus 5 /ID# 275952
Sofiya, Sofia, 1463
- Recruiting
AIPSMPR -d-r Gerganov /ID# 275953
Varna, 9002
Ireland6 sites, 6 recruiting
- Recruiting
Cork University Hospital /ID# 268263
Cork, T12 E8YV
- Recruiting
St James Hospital /ID# 260024
Dublin, Dublin, D08 NHY1
- Recruiting
Beaumont Hospital /ID# 271961
Dublin, D09 XR63
- Recruiting
Tallaght University Hospital /ID# 277000
Dublin, D24 NR0A
Site Coordinator, 01 414 3350
- Recruiting
St Vincents University Hospital /ID# 261237
Elm Park, Dublin, D04 T6F4
- Recruiting
University Hospital Kerry /ID# 266733
Tralee, Kerry, V92 NX94
Israel6 sites, 6 recruiting
- Recruiting
The Lady Davis Carmel Medical Center /ID# 273312
Haifa, 34362
- Recruiting
Hadassah Medical Center-Hebrew University /ID# 273314
Jerusalem, 91120
- Recruiting
Meir Medical Center /ID# 273315
Kfar Saba, Central District, 4428164
- Recruiting
Galilee Medical Center /ID# 275431
Nahariya, 2210001
- Recruiting
The Chaim Sheba Medical Center /ID# 273313
Ramat Gan, Tel Aviv, 5265601
- Recruiting
Tel Aviv Sourasky Medical Center /ID# 273311
Tel Aviv, Tel Aviv, 6423906
Austria4 sites, 4 recruiting
- Recruiting
Medizinische Universitaet Graz /ID# 273765
Graz, Styria, 8010
- Recruiting
Krankenhaus Der Barmherzigen Brueder Graz /ID# 273764
Graz, Styria, 8020
- Recruiting
Landesklinikum Stockerau /ID# 275618
Stockerau, Lower Austria, 2000
- Recruiting
Rheuma-Zentrum Wien-Oberlaa GmbH /ID# 275617
Vienna, State of Vienna, 1100
Argentina3 sites, 3 recruiting
- Recruiting
Cer Instituto Médico /ID# 274445
Quilmes, Buenos Aires, 1878
- Recruiting
Instituto Médico Río Cuarto /ID# 274421
Río Cuarto, Córdoba Province, 5800
- Recruiting
Instituto Medico de Alta Complejidad San Isidro S.A. /ID# 274417
San Isidro, Buenos Aires, 1642
Taiwan3 sites, 3 recruiting
- Recruiting
Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare /ID# 274352
New Taipei City, 235
- Recruiting
Taichung Veterans General Hospital /ID# 274896
Taichung, 407
- Recruiting
National Taiwan University Hospital /ID# 280714
Taipei, 100
Czechia2 sites, 2 recruiting
- Recruiting
MAPO revma /ID# 272409
Ostrava, Ostrava-mesto, 710 00
- Recruiting
Fakultni Nemocnice Plzen /ID# 276061
Pilsen, Praha 17, 301 00
Poland2 sites, 2 recruiting
- Recruiting
Indywidualna Specjalistyczna Praktyka Lekarska dr hab.n.med.Katarzyna Pawlak-Buś /ID# 276483
Poznan, Greater Poland Voivodeship, 61-324
Site Coordinator, +48 601 446 031
- Recruiting
SOMED Renata Sokolik /ID# 276480
Wroclaw, Lower Silesian Voivodeship, 52-317
Saudi Arabia2 sites, 2 recruiting
- Recruiting
Imam Abdulrahman Bin Faisal University /ID# 277716
Dammam, Eastern Province, 34212
- Recruiting
King Saud University /ID# 279463
Riyadh, Riyadh Region, 12372
About this study
Official title: Prospective Multi-country, Real-world, Multi-arm Study of Treatment PErsistence With RISankizumab in Psoriatic Arthritis (PERIS)
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. This study aims to describe the long term usage and effectiveness with risankizumab (RZB) relative to other advanced therapeutic options for the management of PsA in daily clinical practice.
Risankizumab is an approved drug for the treatment of psoriatic arthritis. The study will not be conducted in the United States, however it will be conducted in approximately 15 countries and include at least 900 and up to 1200 participants with a 2 to1 ratio of participant allocation between participants receiving risankizumab and participants receiving other advanced therapeutic agents.
Read more
The therapy is prescribed in the usual manner in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population, and indication. All study visits will occur during routine clinical practice and participants will be followed for 24 months.
There is expected to be no additional burden for participants in this study.
- Conditions
- Psoriatic Arthritis
- Keywords
- Risankizumab, Skyrizi
- Medical subject headings
- Arthritis, Psoriatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Biologic Disease-Modifying Antirheumatic Drugs (bDMARD) | Participants will receive bDMARDs as prescribed by their physician according to local label. | |
| Risankizumab | Participants will receive risankizumab as prescribed by their physician according to local label. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants that show persistence in treatment until 24 months
Persistence over 24 months, defined as a participant who starts PsA treatment and is still on the same therapy until 24 months.
Measured: 24 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jan 2025
- Study start31 Jan 2025
- Primary completionJan 2029 (estimated)
- Study completionFeb 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Psoriatic ArthritisStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06764693
- Sponsor's protocol ID
- P24-390
- Acronym
- PERIS
- Status last verified
- Feb 2026
- First submitted
- 2 Jan 2025
- Last updated
- 17 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Multi-country, Real-world, Multi-arm Study of Treatment PErsistence With RISankizumab in Psoriatic Arthritis (PERIS)
- ClinicalTrials.gov ID
- NCT06764693
- Acronym / sponsor ID
- PERIS / P24-390
- Conditions
- Psoriatic Arthritis
- Keywords
- Risankizumab, Skyrizi
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,200 participants (estimated)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 31 Jan 2025 (actual)
- Primary completion
- Jan 2029 (estimated)
- Study completion
- Feb 2029 (estimated)
- First posted
- 8 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. This study aims to describe the long term usage and effectiveness with risankizumab (RZB) relative to other advanced therapeutic options for the management of PsA in daily clinical practice.
Risankizumab is an approved drug for the treatment of psoriatic arthritis. The study will not be conducted in the United States, however it will be conducted in approximately 15 countries and include at least 900 and up to 1200 participants with a 2 to1 ratio of participant allocation between participants receiving risankizumab and participants receiving other advanced therapeutic agents.
The therapy is prescribed in the usual manner in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population, and indication. All study visits will occur during routine clinical practice and participants will be followed for 24 months.
There is expected to be no additional burden for participants in this study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Biologic Disease-Modifying Antirheumatic Drugs (bDMARD) | – | –Participants will receive bDMARDs as prescribed by their physician according to local label. |
| Risankizumab | – | –Participants will receive risankizumab as prescribed by their physician according to local label. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants that currently are treated with Risankizumab or other advanced treatment options for the management of active psoriatic arthritis in clinical practice.
Key inclusion criteria (2 listed)
- Participant with a clinical diagnosis of psoriatic arthritis (PsA) with symptom onset at least 6 months prior to the Screening visit and fulfillment of ClASsification for Psoriatic ARthritis (CASPAR) at Baseline visit to confirm that the participant has active disease.
- Participant must have demonstrated an inadequate response to at least 1 Disease-modifying antirheumatic drug (DMARD) (with max 50% Biologic DMARD-Inadequate Response); alternatively, participant must have demonstrated an intolerance to or contraindication for csDMARDs as determined by the investigator.
Key exclusion criteria (1 listed)
- Participants demonstrated an inadequate response to three or more bDMARDs/targeted synthetic DMARDs (tsDMARDs).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of participants that show persistence in treatment until 24 months
Time frame: 24 Months
Persistence over 24 months, defined as a participant who starts PsA treatment and is still on the same therapy until 24 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Psoriatic Arthritis
Active, not recruitingPhase 1
Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Active, not recruitingPhase 3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
Psoriatic Arthritis (PsA)
RecruitingObservational study
Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
Axial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA)
RecruitingObservational study
PsoBest - The German Psoriasis Registry
Psoriasis, Psoriatic-arthritis
Not yet recruitingPhase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)
Psoriatic Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
ABBVIE INC. study director
AbbVie
132 sites in 15 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Psoriatic Arthritis, run by AbbVie at 132 sites in 15 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 132 sites in France, Germany, Greece, Italy, Spain and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shari Chapman (844-663-3742, shari.chapman@abbvie.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants that show persistence in treatment until 24 months (time frame: 24 Months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.